Story perspectives

Oncotype DX Test Revolutionizes Breast Cancer Treatment Decisions

10/25/2025

46 4

Summary

Story summary

The Oncotype DX Breast Recurrence Score test, introduced in the early 2000s, analyzes 16 genes in a tumor to guide chemotherapy decisions.
It yields a 0-to-100 score that indicates the likelihood of benefiting from chemotherapy.
About 30% of patients receive clear guidance from the test, enabling more precise treatment plans.
Patients weigh the immediate effects of chemotherapy against long-term risks, as Tara Hayes faced significant health concerns with her cancer.

1 of 1

Story summary

The Oncotype DX Breast Recurrence Score test, introduced in the early 2000s, analyzes 16 genes in a tumor to guide chemotherapy decisions.
It yields a 0-to-100 score that indicates the likelihood of benefiting from chemotherapy.
About 30% of patients receive clear guidance from the test, enabling more precise treatment plans.
Patients weigh the immediate effects of chemotherapy against long-term risks, as Tara Hayes faced significant health concerns with her cancer.